PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 13):
The antibody of  claim 9 , wherein the CDR-H3 comprises the sequence of: (i) (SEQ\u2003ID\u2003NO:\u2003228) JRIIXFTDYVMDA;   (ii) (SEQ\u2003ID\u2003NO:\u2003229) SJIIXFTDYVMDA;   (iii) (SEQ\u2003ID\u2003NO:\u2003230) SRIJXFTDYVMDA;   (iv) (SEQ\u2003ID\u2003NO:\u2003231) SRIIXFTDYVMDA;   (v) (SEQ\u2003ID\u2003NO:\u2003232) SRIIXJTDYVMDA;   (vi) (SEQ\u2003ID\u2003NO:\u2003233) SRIIXFTDYVJDA;   (vii) (SEQ\u2003ID\u2003NO:\u2003234) SRIIXFTDYVMJA;   (viii) (SEQ\u2003ID\u2003NO:\u2003235) SRIIXFTDYVMDJ; or\n (ix) a variant of any one of (ii) to (iii) or (v) to (viii) comprising an additional J amino acid in place of a recited amino acid that is represented by a J in SEQ ID NO: 173.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7436064569729353
- 35 USC 102 Novelty (BERT): 0.5350847410584653
- Combined Prediction Score: 0.7227542853814883
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 231.37132959495307

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test